A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Inclusion Criteria:

• Participant must have completed the last visit of an eligible study period oforiginating study.
• Participant must be willing to follow the birth control measures during and afterstudy treatment if woman of childbearing potential.

Exclusion Criteria:

• Participant must not have an unstable or uncontrolled illness, including but notlimited to a cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal,endocrine, hematologic, or neurologic disease or abnormal lab results, that the studyinvestigator thinks makes it unsafe or inappropriate for the participant toparticipate in this study.
• Participant must not have stopped taking mirikizumab during a previous study or if thestudy investigator thinks restarting mirikizumab would create an unacceptable risk tothe participant.